Table 1.
Characterizations of all the strains in the panel.
| Species | Strain nr | Visit 1 | Sampling site 2 | MIC AZM 3 | AZM S/R 4 | MIC CRO 3 | CRO S/R 4 |
|---|---|---|---|---|---|---|---|
| N. gonorrhoeae | MO00014/1 | 1 | Anal | 2 | R | <0.016 | S |
| N. gonorrhoeae | MO00020/1 | 1 | Anal | 0.75 | S | <0.016 | S |
| N. gonorrhoeae | MO00023/1 | 1 | Anal | 0.19 | S | 0.016 | S |
| N. gonorrhoeae | MO00038/1 | 1 | Anal | 0.25 | S | 0.016 | S |
| N. gonorrhoeae | MO00044/1.3 | 1 | Anal | 0.25 | S | 0.016 | S |
| N. meningitidis | MO0003/1 | 1 | Oral | 1 | S | <0.016 | S |
| N. meningitidis | MO00012/1 | 1 | Oral | 0.5 | S | <0.016 | S |
| N. meningitidis | MO00015/1 | 1 | Oral | 1 | S | <0.016 | S |
| N. meningitidis | MO00015/2 | 1 | Oral | 0.75 | S | <0.016 | S |
| N. meningitidis | MO00021/1 | 1 | Oral | 1.5 | R | <0.016 | S |
| N. oralis | MO00018/1 | 1 | Oral | 4 | R | 0.094 | S |
| N. oralis | MO00032/1 | 2 | Oral | 4 | R | 0.094 | S |
| N. mucosa | MO00012/2 | 1 | Oral | 24 | R | 0.064 | S |
| N. mucosa | MO00029/2 | 2 | Oral | 16 | R | 0.047 | S |
| N. mucosa | MO00018/2 | 1 | Oral | 6 | R | 0.125 | S |
| N. subflava | MO0003/2 | 1 | Oral | >256 | R | 0.75 | R |
| N. subflava | MO0009/1 | 1 | Oral | 3 | R | 0.023 | S |
| N. subflava | MO0009/2 | 1 | Oral | >256 | R | 0.032 | S |
| N. subflava | MO00027/1 | 2 | Oral | 24 | R | 0.023 | S |
| N. subflava | MO00027/2 | 2 | Oral | >256 | R | 0.75 | R |
| N. subflava | MO00029/1 | 2 | Oral | >256 | R | 0.064 | S |
| N. subflava | MO00036/1 | 2 | Oral | >256 | R | 0.125 | S |
| N. subflava | MO00036/2 | 2 | Oral | >256 | R | 0.125 | S |
| N. subflava | MO00041/1 | 2 | Oral | >256 | R | 0.75 | R |
| N. subflava | MO00045/1 | 1 | Oral | 6 | R | 0.047 | S |
| N. subflava | MO00049/1 | 2 | Oral | >256 | R | 0.032 | S |
1 Visit of patient; 1 = day 0, before treatment; 2 = day 14, after treatment. 2 Sampling site: oropharyngeal (oral) and anorectal (anal) swabs. 3 Minimum inhibitory concentrations of azithromycin (AZM) and ceftriaxone (CRO). 4 Breakpoint according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST); azithromycin (AZM) resistant (R) > 1 mg/L; ceftriaxone (CRO) resistant (R) ≥ 0.125 mg/L.